Physician profile
Benjamin Giarmo
NPI 1457766594
$20,583.29
in general payments reported to CMS, 2019-2025
31 companies · $3,608 in 2025
The $3,608 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,939 · 2022: $5,981 · 2023: $4,555 · 2024: $3,501 · 2025: $3,608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Consulting Fee: $800 · Education: $398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,465.00 |
| Consulting Fee | $800.00 |
| Education | $398.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $8,424.28 | 2021-2025 | Tremfya, Remicade, Stelara |
| Abbvie INC. | $2,449.92 | 2021-2025 | |
| Ucb, INC. | $1,332.22 | 2021-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $1,021.60 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $892.84 | 2021-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $868.68 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Novartis Pharmaceuticals Corporation | $820.15 | 2021-2025 | |
| Dermavant Sciences, INC. | $676.93 | 2023-2024 | Vtama |
| Lilly USA, LLC | $610.34 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $524.06 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $443.08 | 2021-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $422.27 | 2021-2025 | Nemluvio, Aklief |
| Pfizer INC. | $408.75 | 2021-2024 | |
| Incyte Corporation | $357.95 | 2021-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $161.48 | 2023-2025 | Zoryve |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $155.51 | 2024-2025 | Vtama, Hadlima |
| Mayne Pharma Commercial LLC | $133.13 | 2021-2023 | |
| Janssen Scientific Affairs, LLC | $129.63 | 2022 | |
| Mallinckrodt Hospital Products INC. | $105.96 | 2024-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.88 | 2023-2024 | Cyltezo, Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $88.09 | 2021-2023 | Jublia |
| Amgen INC. | $74.79 | 2023 | Otezla |
| Sandoz INC. | $73.94 | 2024-2025 | Hyrimoz |
| Vyne Pharmaceuticals INC. | $59.78 | 2021 | |
| Almirall LLC | $50.23 | 2021 | |
| Journey Medical Corporation | $48.94 | 2022-2025 | |
| Kyowa Kirin, INC. | $39.88 | 2021-2022 | |
| Biofrontera INC. | $31.19 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Biocon Biologics INC | $28.28 | 2024 | Hulio |
| Verrica Pharmaceuticals INC. | $23.11 | 2024 | Ycanth |
| Lnhc, INC | $20.40 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Giarmo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.